Antiarrhythmic drug therapy: What is certain and what is to come

European Heart Journal, Supplement

Volumn 5, Issue H, 2003, Pages

  Capucci, Alessandro ^a   Aschieri, D ^a  

^a GENERAL HOSPITAL   (Italy)

Author keywords

Antiarrythmic therapy; Atrial fibrillation

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DISOPYRAMIDE; DOFETILIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL;

CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFICACY; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART RATE; HEART VENTRICLE CONTRACTION; HEART VENTRICLE TACHYCARDIA; HUMAN; LIVER TOXICITY; LUNG TOXICITY; PHOTOSENSITIVITY; POLYNEUROPATHY; PRIORITY JOURNAL; SINUS BRADYCARDIA; SINUS RHYTHM; THYROID DISEASE; TORSADE DES POINTES; URINE RETENTION; XEROSTOMIA;

EID: 0141960858     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90018-6     Document Type: Conference Paper

References (65)

1. Hohnloser SH, Kuch KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF) - a randomised trial. Lancet 2000;356:1789-94.
2. Louis A, Cleland JG, Crabbe S, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001;3:381-7.
3. Wyse DG, Waldo AL, DiMarco JP, et al. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33.
4. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834-40.
5. Zehender M, Hohnloser S, Muller B, et al. Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992;19:1054-9.
6. Halinen MO, Huttunen M, Paakkinen S, Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 1995;76:495-8.
7. Volgman AS, Carberry PA, Stambler B, et al. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter and fibrillation. J Am Coll Cardiol 1998;31:1414-9.
8. Madrid AH, Moro C, Marin-Huerta E, et al. Comparison of fiecainide procainamide in cardioversion of atrial fibrillation. Eur Heart J 1993;14:1127-31.
9. Capucci A, Lenzi T, Boriani G, et al. Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or only systemic hypertension. Am J Cardiol 1992;70:69-72.
10. Capucci A, Boriani G, Rubino I, et al. A controlled study on oral orat propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol 1994;43:305-13.
11. Azpitarte J, Alvares M, Baun O, et al. Value of single oral loading dose propafenone in converting recent onset atrial fibrillation. Results of a randomized, double-blind, controlled study. Eur Heart J 1997;18:1649-54.
12. Capucci A, Villani GQ, Aschieri D, et al. Safety of oral propafenone in the conversion of recent onset atrial fibrillation to sinus rhythm: a prospective parallel placebo-controlled multicenter study. Int J Cardiol 1999;68:187-96.
13. Suttorp MJ, Kingma JH, Jessurun ER, et al. The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 1990;16:1722-7.
14. Suttorp MJ, Kingma JH, Lie-A-Huen L, et al. Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation of flutter to sinus rhythm. Am J Cardiol 1989;63:693-6.
15. Vos MA, Golitsyn RS, Stangl K, et al. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibultilide/ Sotalol Comparator Study Group. Heart 1998;79:568-75.
16. Galve E, Rius T, Ballester R, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. J Am Coll Cardiol 1996;27:1079-82.
17. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated doses of ibutilide for rapid conversion of atrial fibrillation and flutter. Ibutilide Repeat Dose Study Investigators. Circulation 1996;94:1613-21.
18. Platia EV, Michelson EL, Porterfield JK, et al. Esmolol versus verapamil in the acute treatment of atrial fibrillation or atrial flutter. Am J Cardiol 1989;63:925-9.
19. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001;37:542-7.
20. Ellenbogen KA, Stambter BS, Wood MA, et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 1996;28:130-6.
21. Peuhkurinen K, Niemela M, Ylitalo A, et al. Effectiveness of amiodarone as a single oral dose for recent-onset atrial fibrillation. Am J Cardiol 2000;85:462-5.
22. Greenbaum RA, Campbell TJ, Channer KS, et al. Conversion of atrial fibrillation and maintenance of sinus rhythm by dofetilide. The EMERALD study (European and Australian Multicenter Evaluative Research on atrial fibrillation Dofetilide) Study [abstract]. Circulation 1998;98:1633.
23. Singh S, Zoble RG, Yellen L, et al. Efficacy and safety of orat dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 2000;102:2385-90.
24. Norgaard BL, Wachtell K, Christensen PD, et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 1999;137:1062-9.
25. Botto GL, Bonini W, Broffoni T, et al. Regular ventricular rhythms before conversion of recent onset atrial fibrillation to sinus rhythm. Pacing Clin Electrophysiol 1994;17:2114-17.
26. Fatk RH, Pollak A, Singh SN, et al. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J Am Coll Cardiol 1997;29:385-90.
27. Lindeboom JE, Kingma JH, Crijns HJ, et al. Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. Am J Cardiol 2000;85:1031-3.
28. Vitolo E, Tronci M, Larovere MT, et al. Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;36:431-44.
29. Chun SH, Sager PT, Stevenson WG, et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
30. Horowitz LN, Spielman SR, Greenspan AM, et al. Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402-7.
31. Tuzcu EM, Gilbo J, Masterson M, et al. The usefulness of amiodarone in management of refractory supraventricular tachyarrhythmias. Cleve Clin J Med 1989;56:238-42.
32. Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913-20.
33. Torp-Pederson C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmias and Mortality on Dofetilide Study Group. N Engl J Med 1999;341:857-65.
34. Giri S, White CM, Dunn AB, et al. Oral amiodarone for prevention of atrial fibrillation after open heart surgery, the Atrial Fibrillation Suppression Trial (AFIST): a randomised placebo-controlled trial. Lancet 2001;357:830-6.
35. Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 1991;67:713-17.
36. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrence of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 1989;80:1557-70.
37. UK Propafenone PSVT Study Group. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. Circulation 1995;92:2550-7.
38. Deedwania PC, Singh BN, Ellenbogen K, et al. Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). The Department of Veterans Affairs CHF-STAT Investigators. Circulation 1998;98:2574-9.
39. O'Keeffe DB, Nicholls DP, Morton P, et al. Maintenance of sinus rhythm after elective cardioversion from chronic stable atrial fibrillation: amiodarone vs quinidine [abstract]. Br Heart J 1984;51:103.
40. Bellandi F, Simonetti I, Leoncini M, et al. Long-term efficacy and safety of propafenone and sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001;88:640-5.
41. Lee SH, Chen SA, Chiang CE, et al. Comparison of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. J Intern Med 1996;239:253-60.
42. Clementy J, Dulhoste MN, Laiter C, et al. Flecainide acetate in the prevention of paroxysmal atrial fibrillation: a nine-month follow-up of more than 500 patients. Am J Cardiol 1992;70:44A-49A.
43. Kochiadakis GE, Igoumenidis NE, Marketou ME, et al. Low dose amiodarone and sotalol in the treatment of recurrent symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000;84:251-7.
44. Coplen SE, Antman EM, Berlin JA, et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106-16
45. Manning WJ, Silverman DI, Gordon SP, et al. Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. N Engl J Med 1993;328:750-5.
46. Klein AL, Grimm RA, Murray RD, et al. Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001;344:1411-20.
47. Capucci A, Villani GQ, Aschieri D, et al. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J 2000;21:66-73.
48. Kochiadakis GE, Igoumenidis NE, Solomou MC, et al. Efficacy of amiodarone for the termination of persistent atrial fibrillation. Am J Cardiol 1999;83;58-61.
49. Bernard EO, Schmid ER, Schmidlin D, et al. Ibutilide versus amiodarone in atrial fibrillation: a double-blinded, randomized study. Crit Care Med 2003;31:1031-4.
50. Al-Dashti, Sami M. Dofetilide: a new class III antiarrhythmic agent. Can J Cardiol 2001;17:63-7.
51. Oral H, Souza J, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 1999;340:1849-54.
52. Bianconi L, Mennuni M, Lukic V, et al. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: a placebo-controlled study. J Am Coll Cardiol 1996;28:700-6.
53. Veloso HH. Effects of oral sotalol administration before electrical cardioversion of persistent atrial fibrillation. Eur Heart J 2001;22:1512-14.
54. Lindell P, Svenarud P, Albage A, et al. Electrical conversion of atrial fibrillation. Superior effects of biphasic transthoracic method when compared with the conventional monophasic method [In Swedish]. Lakartidningen 2001;98:3319-21.
55. Van Gelder JC, Crijns HJ, van Gilst WH, et al. Effects of flecainide on the atrial defibrillation threshold. Am J Cardiol 1989;63:112-14.
56. Reimold SC, Cantillon CO, Friedman PL, et al. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-63.
57. Anonymous. Atrial Fibrillation Follow-up Investigation of Rhythm Management: the AFFIRM study desisn. The Planning and Steering Committee of the AFFIRM study for the NHLBI AFFIRM investisators. Am J Cardiol 1997;79:1198-202.
58. Kuhlkamp V, Schirdewan A, Stangl K, et al. Use of metoprolol CR/XL to maintain sinus rhythm after conversion from persistent atrial fibrillation: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 2000;36:139-46.
59. Nakazawa H, Lythall DA, Noh J, et al. Is there a place for the late cardioversion of atrial fibrillation? A long-term follow-up study of patients with post-thyrotoxic atrial fibrillation. Eur Heart J 2000;21:327-33.
60. Reiffel JA. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific data-driven decision. Cardiology 1998;82:72N-81N7.
61. Clemett D, Markham A. Azimilide. Drugs 2000;59:271-7.
62. Wang J, Feng J, Nattel S. Class III antiarrhythmic drug action in experimental atrial fibrillation. Differences in reverse use dependence and effectiveness between D-sotalol and the new antiarrhythmic drug ambasilide. Circulation 1994;90:2032-40.
63. Corey AE, Al-Khalidi H, Brezovic C, et al. Azimilide pharmacokinetics upon multiple oral dosing [abstract]. Clin Pharm Ther 1997;61:205.
64. Pritchett EL, Page RL, Connolly SJ, et al. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators. J Am Coll Cardiol 2000;36:794-802.
65. Geller JC, Geller M, Carison MD, et al. Efficacy and safety of moricizine in the maintenance of sinus rhythm in patients with recurrent atrial fibrillation. Am J Cardiol 2001;87:172-7.